Fonte: European urology. Unidade: FM
Assuntos: NEOPLASIAS PROSTÁTICAS, METÁSTASE NEOPLÁSICA, RADIOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PARKER, Christopher C. e DALL'OGLIO, Marcos Francisco. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. European urology, v. 73, n. 3, p. 427-435, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.eururo.2017.06.021. Acesso em: 16 out. 2024.APA
Parker, C. C., & Dall'Oglio, M. F. (2018). Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. European urology, 73( 3), 427-435. doi:10.1016/j.eururo.2017.06.021NLM
Parker CC, Dall'Oglio MF. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial [Internet]. European urology. 2018 ; 73( 3): 427-435.[citado 2024 out. 16 ] Available from: https://doi.org/10.1016/j.eururo.2017.06.021Vancouver
Parker CC, Dall'Oglio MF. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial [Internet]. European urology. 2018 ; 73( 3): 427-435.[citado 2024 out. 16 ] Available from: https://doi.org/10.1016/j.eururo.2017.06.021
